Summary Prostatic adenocarcinoma commonly metastasizes to bone. Unlike most other bony secondaries, the majority of skeletal prostatic metastases are osteoblastic rather than osteolytic i nature. Several growth factors which are known to stimulate bone formation are expressed in benign and malignant prostate cells. bi none has been specifically linked to osteoscierotic metastases. Bone morphogenetic proteins (BMPs) induce ectopic bone formation in vivo. We have reported previously that BMP-6 mRNA and protein are expressed in the majority of primary prostatic carcinomas with established skeletal metastases but rarely in clinically organ-confined tumours. This study examines the expression of BMP-6 mRNA in matched prostatic primary and secondary bony lesions and in isolated skeletal metastases from prostatic adenocarcinomas, as well as other common human malignancies, by in situ hybridization. BMP-6 mRNA was detected in 11 out of 13 bone metastases from prostate carcinoma and in three paired samples of primary prostate carcinoma and matching skeletal metastasis. Weak signals for BMP-6 were also present in 5 out of 17 skeletal deposits from non-prostatic malignancies. BMP-6 mRNA appears to be strongly expressed in prostatic adenocarcinomas, both in the primary tumour and in bone metastases. It is also expressed, though less frequentty, in skeletal metastases from other human carcinomas. Our findings suggest that BMP-6 may hold potential as an attractive marker and possible mediator of skeletal metastases, particularly in prostate carcinoma.
Metastases are the most common neoplastic lesions in bone. and more than 80%-7 of the tumours are accounted for by a limited number of primary malignancies (Orr et al. 1995) . These include carcinomas of the breast, prostate. thyroid. kidney and lungy. Normal bone is being remodelled continuously with new bone formation by osteoblasts and bone degradation by osteoclasts. In the presence of skeletal metastases. there is a disturbance of the fine balance between the two processes. When bone destruction dominates there is net loss of bone mass and the lesion is described as osteolytic. W'hen excessise amounts of new bone formation takes place with less bone destruction. the lesion is described as osteoblastic or osteosclerotic. This type of increased ossification only occurs in relatively acellular skeletal metastases associated with the deselopment of a fibrous stroma. and is particularly common in metastases from prostatic carcinoma (Galasko. 1982) . Human prostatic adenocarcinoma is one of the rare cancers that consistently produces osteoblastic metastases to bone. in approximately 90% of cases. Several growth factors which are known to stimulate osteoblast growth and bone matrix formation are also expressed in benign and malignant prostate cells. These include members of the fibroblast growth factor. insulin-lke growth factor. platelet-denried growth factor and transforming growth factor-beta (TGF-0) families (Bavlink et al. 1993 : Ware. 1993 (Dube and Celeste. 1996) and they are all. except BMP-1. members of the TGF-, superfamily of peptide growth factors. Prostate cancer is the second most common male malignancN in Europe. with over 85 000 cases re-istered every year (Jensen et al. 1990 ). In the United States of America it is the most common malianancx in men. with an estimated 209 900 nesw cases diagnosed in 1997 (Wingo et al. 1997 ).
Skeletal metastases represent the most common cause of morbiditv in men with advanced disease. and there is no clear explanation for their osteoblastic nature.
Pilot work. using the reverse transcriptase pol%-merase chain reaction (RT-PCR) to detect mRNA for BMPs 1-6. showed differential expression in benign and malignant prostatic tissue. w-ith BMP-6 being expressed in over 50% of primars tumours swith established bony secondaries (Bentley et al. 1992 
MATERIALS AND METHODS Tissue
Archival tissue was obtained from 30 patients with established skeletal metastases from different primary cancers. The metastatic lesions were from primary carcinomas of prostate (n = 13). lung In = 8). kidney (n = 2). breast (n = 5). colon (n = 1) and uterus (n = 1). In addition. primary prostatic malignant tissue from 3 of the 13 patients with skeletal secondaries was obtained from transurethral resection specimens. The tissue was fixed in 10%A neutral buffered formalin and specimens containing calcified matenral were decalcified in Gooding and Stewart's decalcification fluid. All tissue samples were processed and embedded in paraffin wax. Sections were cut at 3 gm.
mounted on 3-aminopropyltriethoxysilane (APES)-coated slides and dried overnight at 37C followed by 1 h at 56CC.
BMP-6 nboprobes
A 758-bp fragment of the human BMP-6 cDNA. representing bases 1019-1776 of the published sequence. was amplified by PCR using placental cDNA as the template with the following oligonucleotides: 5'-TCCTGACCTGTrl-lGTFG-3' and 5'-CT CCGTGl IT1T-lTAAGGC-3'. The fragment was cloned in forward and reverse orientation into the pBluescript SK+ vector (Stratagene. UK). DNA sequencing analysis was performed on this fragment and showed it to be identical to the published BMP-6 cDNA sequence (GenBank accession number M38694) (Celeste et al. 1990 ).
Recombinant plasmids were linearized with SmaI and gel purified from low melting point agarose using standard conditions. The purified DNA was subsequently phenol extracted under RNAase-free conditions. ethanol precipitated and resuspended in diethyl-pyrocarbonate-treated water. Sense and antisense riboprobes were synthesized by in vitro transcnption using7T7 RNA polymerase and the Dig-RNA labelling kit (Boehringer Mannheim. UK). Each transcription reaction contained 1 jg of cDNA and the yield of digoxigenin-labelled RNA was estimated by spot-blot analysis.
In situ hybridization
In situ hybridization was performed as previously described (Hamdy et al, 1997 
Statistical analysis
Fisher's exact test was used for statistical analysis. P-values less than 0.05 were considered significant.
RESULTS
Thirty bone metastases. three of which had corresponding primary prostate carcinoma tissue, were studied with the BMP-6 antisense and sense probes. Messenger RNA for BMP-6 was identified in normal osteoblasts in skeletal tissue. This was used as an internal positive control and indicator of mRNA integrity in all the samples investigated. In bone metastases from prostatic adenocarcinomas, positive signals for BMP-6 were observed in 11 out of 13 lesions (85%) compared with 5 out of 17 (29%) skeletal deposits from nonprostatic malignancies (P = 0.0039). These included primary breast (3 out of 5, one of which had mixed osteolytic and osteoblastic changes), lung (1 out of 8) and colon (1 out of 1) carcinomas (Table 1) . No expression of BMP-6 was found in skeletal metastases from primary renal or uterine carcinomas. The hybridization signals, which appeared as purple/black cytoplasmic staining, were intense and homogeneous. In the three paired samples of primary and secondary prostate carcinoma, both lesions expressed BMP-6 and the expression was exclusive to malignant epithelial cells (Figure 1 ). While the majority of these cells in the metastatic lesions showed strong expression of BMP-6, varying degrees of expression were observed in the primary tumours. The signals for BMP-6 observed in secondaries from non-prostatic carcinomas appeared weaker than in primary and secondary prostate carcinoma cells. When hybridization was performed with the BMP-6 sense probe on serial sections, no signals were observed.
DISCUSSION
Since the discovery of BMPs in 1965, research has focused on identification and purification of these proteins (Bauer and Urist, 1981 : Urist et al, 1982 (Lyons et al, 1989 (Lyons et al, , 1990 . Their osteoinductive ability in vivo has also stimulated the development of potential therapeutic applications in reconstructive orthopaedic, periodontal and craniofacial surgery (Wang et al, 1990 ; Stone, 1997) . BMPs are actively involved in bone formation and have the capacity to induce differentiation of mesenchymal cells into cartilage and then into bone. These effects have been observed both in vivo and in vitro (Urist et al, 1983) .
Osteoblasts express BMP as they differentiate to forn mineralized bone (Harris et al, 1994b) , and it has been suggested that BMPs may be involved in directing cells along the osteoblast lineage (Mundy, 1996) . BMPs have also been described in malignant bone tumours, in particular human osteosarcomas Yang. 1990: Yang and Jin, 1990; Yoshikawa et al. 1994a Yoshikawa et al. , 1994b . In nonskeletal cancers, very few efforts have been made to link BMP activity with the development and progression of cancer. This is not surprising in view of the behaviour of most skeletal metastases with increased bone resorption and osteoclastic activity, a process which is not generally associated with BMP activity. However. prostatic adenocarcinoma commonly gives rise to osteosclerotic bone lesions with a predilection for the axial skeleton (Saitoh et al. 1984) . Previous work has demonstrated a potential association between BMP expression, in particular BMP-6, and the presence of skeletal metastases in prostate carcinoma (Bentley et al. 1992; Harris et al, 1994a; Barnes et al, 1995) .
More recently, we have shown that the majority of primary prostatic tumours with established skeletal metastases express BMP-6 both at protein and mRNA levels, while most clinically organ-confined prostatic carcinomas are negative for BMP-6 (Hamdy et al, 1997) .
In this study, we have used in situ hybridization to examine the expression of BMP-6 in matched primary and secondary prostatic adenocarcinomas and in isolated skeletal metastases from prostate carcinomas and other common human malignancies. We found that BMP-6 mRNA is strongly expressed in the majority of skeletal metastases from prostatic adenocarcinomas. Despite our limited number of corresponding primary prostatic tumours. when the three matched samples were examined they were also found to express BMP-6 and the expression was exclusive to the malignant epithelial cells, a finding we have reported recently (Hamdy et al, 1997) . It was interesting to observe that, although present in a minority of skeletal secondaries from other human malignancies. BMP-6 signals in these cases were considerably weaker than in prostatic secondaries.
BMP-6 has been shown previously to be expressed in both normal and malignant prostatic tissue (Harris et al, 1994a) with slightly elevated levels of mRNA expression in the malignant tissue (Bames et al, 1995) . One study by Bentley et al (1992) showed, by RT-PCR, that BMP-6 was selectively expressed in primary prostatic tumours of patients with positive bone scans and absent in non-metastatic tumours, benign tissue and ocular melanoma, which rarely metastasizes to bone, in accordance with our recent findings.
Several studies have suggested that BMPs are involved in the complex process of osteoblast differentiation, but the functional differences between individual BMPs are not well understood. In a bone nodule-forming assay utilizing rat osteoprogenitor cells, BMP-6 was shown to produce larger nodules than BMP-2 and BMP-4 and possibly to act on an earlier stage progenitor cell (Hughes et al, 1995) . Similar findings were reported by Boden et al (1996) , who estimated BMP-6 to be a 2-to 2.5-fold more potent inducer of osteoblastic differentiation than BMP-2 and BMP-4. Osteoblastic extracellular matrix was also shown to increase mRNA levels of BMP-6, but not BMP-2 and BMP-4, in the uncommitted mesenchymal ROB-C26 cells (Shi et al, 1995) . In contrast, BMP-2 and BMP-4 are more potent in inducing an osteoblastic phenotype in bone marrow stromal cells than BMP-6 (Yamaguchi et al, 1996) , and BMP-2 has greater chemotactic effect on in vitro migration of human osteoblasts than BMP-4 and BMP-6 (Lind et al, 1996) . The role of the murine homologue of BMP-6, Vgr-l, in endochondral bone formation was investigated in an elegant study by Gitelman et al (1994) . Chinese hamster ovary (CHO) cells transfected with Vgr-l, when injected subcutaneously into nude mice, were shown to produce tumours with well-developed vasculature and areas of bone and cartilage formation. In comparison, the tumours formed by the parental cells became necrotic and haemorrhagic and, more importantly, lacked the cartilage and bone formation completely.
Benign and malignant prostate cells produce a number of growth factors with mitogenic activity for osteoblasts (Baylink et al, 1993; Ware, 1993) , but none of these factors has been specifically linked to the inreased osteoblastic activity seen in skeletal lesions secondary to prostate cancer. However, some studies have suggested the presence of a mitogen produced by metastatic prostate cancer cells, which stimulates osteoblastic proliferation with high specificity (Koutsilieris et al, 1987a (Koutsilieris et al, , 1987b Perkel et al, 1990) .
There is growing evidence that BMP-6 gene expression is associated with primary prostate carcinomas that have metastasized to bone and their skeletal secondaries.
Although the aim of the current study was not to investigate the role of BMP-6, one could speculate that this potent protein may facilitate the development of skeletal metastases in prostate carcinoma, and may be responsible for their osteoblastic nature. Further studies are warranted to investigate the potential function of BMPs, and BMP-6 in particular, in the progression of early prostate carcinoma to the metastatic phenotype.
